RGEN News and Press, Repligen Corporation From 02/21/19

Repligen Corporation (RGEN) Q4 2018 Earnings Conference Call February 21, 2019 8:30 AM ET Company Participants Sondra Newman – Senior Director-Investor Relations Tony Hunt – President and Chief Executive Officer Jon Snodgres – Chief Financial Officer Confe...

Repligen (NASDAQ: RGEN ): Q4 Non-GAAP EPS of $0.21 in-line; GAAP EPS of $0.12 beats by $0.01 . More news on: Repligen Corporation, Earnings news and commentary, Healthcare stocks news, Read more ...

Record quarterly revenue of $51.9 million represents 25% year-over-year growth, and record annual revenue of $194.0 million represents 37% year-over-year growth Overall organic revenue growth was 25% for the fourth quarter and 17% for the year 2018 WALTHAM, Mass., Feb. 21, 2019 (GL...

AIMC , ARD , ATRO , BG , BRC , CCOI , CJ , CNSL , COMM , DIN , DLPH , DPZ , EME , FND , FOCS , GIL , GOGO , HEES , HL , HRL , HSC , IART , IDA , IDCC , ITGR , MCRN , MFA , NCLH , NEM , OGE , PLAB , PQG , PWR , RGEN , ROCK , RS , SATS , SCL , SFM , SGM...

Repligen (NASDAQ: RGEN ) is scheduled to announce Q4 earnings results on Thursday, February 21st, before market open. More news on: Repligen Corporation, Earnings news and commentary, , Healthcare stocks news, Read more ...

WALTHAM, Mass., Feb. 15, 2019 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its fourth quarter and full year 2018 financial results on Thursday, February 21, 2019. The Company will issue a press release before the market opens and will h...

NEW YORK, NY / ACCESSWIRE / January 28, 2019 / U.S. equities closed higher on Friday as companies continue to report upbeat earnings and Trump and the Democrats agreed to reopen the government until Feb. 15. The Dow Jones Industrial Average climbed 0.75 percent to settle at 24,737.20, while ...

Overview As I previously laid out in my article initiating coverage on Repligen ( RGEN ), they have carved a wide moat niche for themselves in the bioprocessing space thanks to excellent market positioning by the management team. Through organic innovation and bolt-on, tactical acquisition...

Development collaboration integrates Sartorius Stedim Biotech’s BIOSTAT ® STR bioreactors and Repligen’s XCell™ ATF cell retention control technology Customers to benefit from simplified, scalable solutions for intensified cell culture GÖTTINGEN, Ger...

Investing in high-growth stocks can generate outstanding returns when done right. In essence, a stock is simply a share in the ownership of a business, and businesses with superior growth rates tend to generate higher returns for investors over the long term. However, implementing a solid gr...